2024
Prostate Cancer Foundation Screening Guidelines for Black Men in the United States.
Garraway I, Carlsson S, Nyame Y, Vassy J, Chilov M, Fleming M, Frencher S, George D, Kibel A, King S, Kittles R, Mahal B, Pettaway C, Rebbeck T, Rose B, Vince R, Winn R, Yamoah K, Oh W. Prostate Cancer Foundation Screening Guidelines for Black Men in the United States. NEJM Evidence 2024, 3: evidoa2300289. PMID: 38815168, DOI: 10.1056/evidoa2300289.Peer-Reviewed Original ResearchConceptsProstate-specific antigenBaseline PSA testingProstate-specific antigen screeningPSA testingProstate cancerScreening guidelinesBlack menBaseline prostate-specific antigenProstate-specific antigen valuesYears of follow-upProstate cancer deathProstate cancer mortalityScreening of menFull-text reviewComprehensive literature searchRandomized Controlled TrialsNon-black menAnnual screeningFrequency of testingIncrease overdiagnosisFollow-upProstateCohort studyCancer mortalityUnited States
2017
Racial disparities in prostate cancer outcome among prostate-specific antigen screening eligible populations in the United States
Mahal B, Chen Y, Muralidhar V, Mahal A, Choueiri T, Hoffman K, Hu J, Sweeney C, Yu J, Feng F, Kim S, Beard C, Martin N, Trinh Q, Nguyen P. Racial disparities in prostate cancer outcome among prostate-specific antigen screening eligible populations in the United States. Annals Of Oncology 2017, 28: 1098-1104. PMID: 28453693, DOI: 10.1093/annonc/mdx041.Peer-Reviewed Original ResearchConceptsProstate cancer-specific mortalityProstate-specific antigenUnited States Preventive Services Task ForceRisk of prostate cancer-specific mortalityProstate cancer outcomesBlack raceMetastatic diseaseCancer outcomesProstate-specific antigen screeningRate of metastatic diseasePSA screening guidelinesCancer-specific mortalityRisk of poor outcomesStage of presentationPreventive Services Task ForceScreening-eligible ageMultivariate logistic regressionEligible populationNon-black menSEER databaseProstate cancerBlack menScreening guidelinesPoor outcomeRisk regressionRacial disparities in prostate cancer outcome among prostate-specific antigen screening eligible populations in the United States.
Mahal B, Chen Y, Muralidhar V, Mahal A, Choueiri T, Hoffman K, Hu J, Sweeney C, Beard C, Martin N, Feng F, Kim S, Yu J, Trinh Q, Nguyen P. Racial disparities in prostate cancer outcome among prostate-specific antigen screening eligible populations in the United States. Journal Of Clinical Oncology 2017, 35: 18-18. DOI: 10.1200/jco.2017.35.6_suppl.18.Peer-Reviewed Original ResearchProstate cancer-specific mortalityProstate-specific antigenRisk of prostate cancer-specific mortalityProstate-specific antigen screeningProstate cancer outcomesUnited States Preventive Services Task ForceBlack raceMetastatic diseaseCancer outcomesRate of metastatic diseaseCancer-specific mortalityStage of presentationRisk of poor outcomesPreventive Services Task ForceScreening-eligible ageMultivariate logistic regressionEligible populationNon-black menProstate-specificSEER databaseProstate cancerBlack menPoor outcomeRisk regressionBlack patientsOutcomes for men under 65 with high-risk prostate cancer with Medicaid versus private insurance.
Mahal A, Mahal B, Nguyen P, Yu J. Outcomes for men under 65 with high-risk prostate cancer with Medicaid versus private insurance. Journal Of Clinical Oncology 2017, 35: 198-198. DOI: 10.1200/jco.2017.35.6_suppl.198.Peer-Reviewed Original ResearchProstate cancer-specific mortalityHigh-risk prostate cancerProstate cancerTreatment of high-risk prostate cancerInsurance statusCompeting-risks regression modelsHigh-risk CaPPrivately insured menGray's competing-risks regression modelHigh-risk diseaseCancer-specific mortalityEnd Results ProgramMultivariate logistic regressionMetastatic diseaseNon-black menResults ProgramPrivate insuranceInsured menAfrican American menLogistic regressionMetSOutcomesCancerMenMore-than-additive effect
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply